Welcome to our dedicated page for Frontage Hldgs news (Ticker: FTHCY), a resource for investors and traders seeking the latest updates and insights on Frontage Hldgs stock.
Frontage Holdings Corp (FTHCY) is a global contract research organization (CRO) providing integrated drug development services to biopharmaceutical innovators. This page serves as the definitive source for official company announcements, regulatory updates, and strategic developments.
Investors and industry professionals will find curated press releases covering clinical trial milestones, partnership agreements, financial results, and operational expansions. Our aggregation ensures efficient tracking of Frontage’s progress in analytical testing, preclinical research, and global regulatory compliance initiatives.
Key updates are organized for quick scanning, including:
• Clinical trial advancements
• Strategic collaborations
• Regulatory submission milestones
• Operational capacity expansions
Bookmark this page for streamlined access to Frontage’s latest developments in pharmaceutical research services. Check regularly for real-time updates on initiatives impacting drug development timelines and clinical research outcomes.
Frontage Holdings Corporation (OTC:FTHCY) has announced the appointment of Dr. Abdul Mutlib as President of Frontage Laboratories, Canada, marking a strategic expansion of its services in the Canadian market. Dr. Mutlib, who will continue his role as Chief Scientific & Strategy Officer, will oversee operations in Toronto and Vancouver, reporting to Co-CEO Dr. Wentao Zhang.
With over 35 years of R&D experience in pharmaceutical and CRO sectors, Dr. Mutlib will focus on establishing Frontage as a key partner for Canada's growing biotech industry. The appointment aligns with Frontage's strategy to enhance its position as a leading global pharmaceutical Contract Research Organization (CRO).
Frontage Holdings Corporation has announced the promotions of Dr. Abdul Mutlib to CEO and Dr. John Lin to President as of January 3, 2023. Dr. Mutlib has over 12 years of experience with Frontage, leading the Preclinical business, while Dr. Lin has been with the company for over 15 years, focusing on Bioanalytical and Biologics services. Founder Dr. Song Li remains Executive Chairman, emphasizing a focus on strategic growth. The leadership changes aim to enhance operational performance and prepare for future expansion, leveraging their extensive industry experience.
Frontage Laboratories announced a collaboration with Eisai and Biogen to support the bioanalysis of lecanemab (BAN2401) in a phase 3 study for Alzheimer's disease.
The study met aggressive timelines, showcasing Frontage's commitment to addressing medical needs. Notably, the study has delivered favorable results as highlighted in a presentation on November 29, 2022.
Frontage's scientific team contributed to biomarker analysis, reinforcing their role in global clinical research.
